Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux.

Abstract

OBJECTIVE:

To determine the efficacy of proton pump inhibitor (PPI) therapy with esomeprazole on symptoms and signs associated with laryngopharyngeal reflux (LPR).

STUDY DESIGN AND METHODS:

Prospective, double-blind, randomized, placebo-controlled study. Sixty-two patients with a reflux finding score (RFS)>7 and a reflux symptom index (RSI)>13 were enrolled and received either esomeprazole 20 mg twice daily or placebo for three months. RSI and RFS were assessed at baseline, after six weeks, and after three months.

RESULTS:

Reductions of total RSI and RFS as well as of several subscores were significantly higher in the treatment group compared to placebo after three months (P<0.05 each). The difference between study groups was most pronounced for posterior commissure hypertrophy (P<0.01).

CONCLUSION:

In the treatment of LPR-related symptoms a high placebo effect can be observed. However, compared to control, twice-daily PPI treatment for three months demonstrated a significantly greater improvement in laryngeal appearance and LPR symptoms.

• Authors: Oliver Reichel, Holger Dressel, Katrin Wiederänders, Wolfgang J Issing
• Journal: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (Otolaryngol Head Neck Surg) Vol. 139 Issue 3 Pg. 414-20 (Sep 2008) ISSN: 0194-5998 [Print] England
• PMID: 18722223 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Ulcer Agents
• Proton Pump Inhibitors
• Esomeprazole

Topics

• Adult
• Aged
• Anti-Ulcer Agents (administration & dosage, therapeutic use)
• Double-Blind Method
• Esomeprazole (administration & dosage, therapeutic use)
• Female
• Gastroesophageal Reflux (drug therapy)
• Humans
• Hypertrophy
• Hypopharynx (drug effects, pathology, physiopathology)
• Male
• Middle Aged
• Prospective Studies
• Proton Pump Inhibitors (administration & dosage, therapeutic use)